Techniclone Agrees to License Technology

Techniclone Corp., a Tustin developer of cancer treatments, said Thursday that it has tentatively agreed to license one of its technologies to a San Ramon, Calif., company for about $8 million.

The price includes an upfront payment, certain future payments and a royalty.

Techniclone said in a press release that SuperGen Inc. will license its Vascular Targeting Agent technology, which is a therapeutic treatment designed specifically to destroy vascular tumors.

SuperGen said it believes the technology can deliver a wide range of cancer-fighting drugs.